Encompass Health (NYSE:EHC – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.16, Zacks reports. The firm had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.60 billion. Encompass Health had a net margin of 10.17% and a return on equity of 18.62%. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period last year, the firm posted $1.23 earnings per share.
Encompass Health Trading Up 2.0%
Shares of Encompass Health stock traded up $2.58 on Friday, reaching $134.06. The company had a trading volume of 406,636 shares, compared to its average volume of 1,045,923. The firm’s 50 day moving average price is $122.58 and its two-hundred day moving average price is $109.81. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.19 and a current ratio of 1.19. Encompass Health has a 52-week low of $92.77 and a 52-week high of $137.27. The firm has a market cap of $13.23 billion, a PE ratio of 21.04, a PEG ratio of 2.47 and a beta of 0.74.
Encompass Health Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, January 15th. Stockholders of record on Monday, January 4th will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, January 4th. Encompass Health’s payout ratio is 13.68%.
Insider Buying and Selling
In other Encompass Health news, CEO Mark J. Tarr sold 173,148 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the transaction, the chief executive officer directly owned 267,814 shares in the company, valued at $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP John Darby sold 8,906 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.95, for a total value of $1,121,710.70. Following the transaction, the executive vice president owned 75,041 shares of the company’s stock, valued at approximately $9,451,413.95. This represents a 10.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 186,912 shares of company stock valued at $23,434,845 in the last ninety days. 1.80% of the stock is currently owned by corporate insiders.
Encompass Health News Roundup
Here are the key news stories impacting Encompass Health this week:
- Positive Sentiment: Third-quarter results exceeded expectations. Earnings per share were $1.52, versus analysts’ consensus of $1.36, while revenue rose 8.9% year over year to $1.61 billion, slightly above the $1.60 billion estimate. Adjusted EBITDA increased 15.5% to $346.6 million. Encompass Health reports results for third quarter 2026
- Positive Sentiment: Management raised full-year 2026 earnings guidance. The company now expects EPS of $6.23 to $6.37, above the prior range of $6.02 to $6.25 and the $6.11 consensus estimate. Revenue guidance remained approximately $6.5 billion, in line with expectations. Encompass Health climbs after Q3 results top expectations and guidance is raised
- Positive Sentiment: Operating indicators remained supportive. Third-quarter discharges rose 5.7%, same-store discharges increased 3.0%, and net patient revenue per discharge grew 4.0%, suggesting both volume and pricing contributed to the performance.
- Neutral Sentiment: Valuation-focused coverage was favorable. Zacks highlighted EHC as a strong value stock, which may reinforce investor interest, although the article did not announce a new company catalyst. Why Encompass Health is a Strong Value Stock
- Negative Sentiment: Reported insider activity was entirely selling. Quiver Quantitative data showed eight insider sales and no purchases over the past six months, including sales by senior executives. This could temper sentiment, although insider transactions may reflect personal financial decisions rather than a fundamental outlook.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on EHC shares. Raymond James Financial set a $150.00 target price on shares of Encompass Health in a research note on Monday, September 28th. Wall Street Zen cut Encompass Health from a “buy” rating to a “hold” rating in a report on Saturday, October 17th. Truist Financial set a $156.00 price objective on Encompass Health in a research report on Friday. UBS Group reissued a “buy” rating and set a $165.00 price objective on shares of Encompass Health in a research note on Friday. Finally, TD Cowen upped their price objective on shares of Encompass Health from $125.00 to $140.00 and gave the company a “buy” rating in a report on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Encompass Health has an average rating of “Buy” and an average target price of $152.00.
Get Our Latest Stock Analysis on Encompass Health
Encompass Health Company Profile
Encompass Health Corporation (NYSE:EHC) is a healthcare services company that operates inpatient rehabilitation hospitals in the United States and Puerto Rico. Its hospitals provide intensive rehabilitation to patients recovering from conditions such as stroke, brain and spinal cord injuries, neurological disorders, amputations, hip fractures and other serious illnesses or injuries.
The company’s services typically include nursing care, physical therapy, occupational therapy, speech and language therapy, respiratory therapy and medical management.
Further Reading
- Five stocks we like better than Encompass Health
- Microsoft Earnings Expose a Growing Divide in the Magnificent 7 AI Trade
- Silicon Shock: Intel’s 25% Valuation Reset
- Advanced Micro Devices’ Meta Platforms Partnership Goes Beyond a $1 Billion Investment
- Chipotle’s $32 Floor: Is a Major Stock Rebound Coming?
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.
